- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05638295
Тестирование использования AMG 510 (Sotorasib) и панитумумаба в качестве таргетного лечения солидных опухолей с мутацией KRAS G12C (испытание лечения ComboMATCH)
Рандомизированное исследование фазы II применения AMG 510 (соторасиба) с панитумумабом или без него при запущенных солидных опухолях: исследование лечения ComboMATCH
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Обзор исследования
Статус
Условия
Подробное описание
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 (sotorasib) alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except colorectal carcinoma [CRC] and non-small cell lung carcinoma [NSCLC]) as measured by progression free survival (Cohort 1).
II. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by response rate (Cohort 2).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab as compared to AMG 510 alone in patients with advanced/metastatic KRAS G12C mutated solid tumors (except CRC and NSCLC) as measured by response rate, disease control rate, and overall survival (Cohort 1).
II, To evaluate the efficacy of the combination of AMG 510 (sotorasib) and panitumumab in patients with advanced/metastatic KRAS G12C mutated solid tumors that have progressed on a prior KRAS G12C inhibitor as measured by disease control rate, progression free survival (PFS), and overall survival (Cohort 2).
III. To further evaluate the safety and tolerability of the combination of AMG 510 (sotorasib) and panitumumab.
IV. To collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (DNA) (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol.
CORRELATIVE EXPLORATORY OBJECTIVES:
I. To investigate the impact of concomitant mutations on the clinical benefit. II. To evaluate if changes in circulating tumor DNA (ctDNA) over time correlate with response to treatment.
III. To evaluate the relative mutant allele fraction of KRAS mutation as a predictor of clinical benefit.
IV. To evaluate if ERK 1/2 and PI3K pathway activation correlate with response and/or resistance.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients who have never received a KRAS G12C inhibitor are randomized to arms A or B.
ARM A: Patients receive sotorasib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and computed tomography (CT) or magnetic resonance imaging (MRI) on study.
ARM B: Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study.
COHORT II: Patients who have received a KRAS G12C inhibitor are assigned to arm C.
ARM C: Patients receive combination therapy as in Arm A.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months for up to 36 months.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- University of Alabama at Birmingham Cancer Center
-
Mobile, Alabama, Соединенные Штаты, 36688
- University of South Alabama Mitchell Cancer Institute
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Соединенные Штаты, 90025
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Palo Alto, California, Соединенные Штаты, 94304
- VA Palo Alto Health Care System
-
-
Florida
-
Aventura, Florida, Соединенные Штаты, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Соединенные Штаты, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Coral Springs, Florida, Соединенные Штаты, 33065
- UM Sylvester Comprehensive Cancer Center at Coral Springs
-
Deerfield Beach, Florida, Соединенные Штаты, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Hollywood, Florida, Соединенные Штаты, 33021
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Jacksonville, Florida, Соединенные Штаты, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Соединенные Штаты, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Соединенные Штаты, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Соединенные Штаты, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Соединенные Штаты, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Соединенные Штаты, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Соединенные Штаты, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Соединенные Штаты, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Соединенные Штаты, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Barrington, Illinois, Соединенные Штаты, 60010
- Advocate Good Shepherd Hospital
-
Chicago, Illinois, Соединенные Штаты, 60612
- University of Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Соединенные Штаты, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Соединенные Штаты, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Соединенные Штаты, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Соединенные Штаты, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Соединенные Штаты, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Downers Grove, Illinois, Соединенные Штаты, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Соединенные Штаты, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Соединенные Штаты, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Соединенные Штаты, 60123
- Advocate Sherman Hospital
-
Hazel Crest, Illinois, Соединенные Штаты, 60429
- Advocate South Suburban Hospital
-
Libertyville, Illinois, Соединенные Штаты, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Соединенные Штаты, 60048
- AMG Libertyville - Oncology
-
Mattoon, Illinois, Соединенные Штаты, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Соединенные Штаты, 60153
- Loyola University Medical Center
-
Normal, Illinois, Соединенные Штаты, 61761
- Carle Cancer Institute Normal
-
Normal, Illinois, Соединенные Штаты, 61761
- Carle BroMenn Medical Center
-
O'Fallon, Illinois, Соединенные Штаты, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Соединенные Штаты, 60453-2699
- Advocate Christ Medical Center
-
Oak Lawn, Illinois, Соединенные Штаты, 60453
- Advocate Outpatient Center - Oak Lawn
-
Palos Heights, Illinois, Соединенные Штаты, 60463
- Advocate High Tech Medical Park
-
Park Ridge, Illinois, Соединенные Штаты, 60068
- Advocate Lutheran General Hospital
-
Shiloh, Illinois, Соединенные Штаты, 62269
- Memorial Hospital East
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Соединенные Штаты, 62702
- Springfield Clinic
-
Springfield, Illinois, Соединенные Штаты, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Соединенные Штаты, 61801
- Carle Cancer Center
-
-
Iowa
-
Ankeny, Iowa, Соединенные Штаты, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Des Moines, Iowa, Соединенные Штаты, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Соединенные Штаты, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Соединенные Штаты, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maine
-
Brewer, Maine, Соединенные Штаты, 04412
- Lafayette Family Cancer Center-EMMC
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Соединенные Штаты, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Соединенные Штаты, 20889-5600
- Walter Reed National Military Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Соединенные Штаты, 48124
- Corewell Health Dearborn Hospital
-
Farmington Hills, Michigan, Соединенные Штаты, 48336
- Corewell Health Farmington Hills Hospital
-
Flint, Michigan, Соединенные Штаты, 48503
- Hurley Medical Center
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Соединенные Штаты, 48503
- Cancer Hematology Centers - Flint
-
Lansing, Michigan, Соединенные Штаты, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Соединенные Штаты, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Royal Oak, Michigan, Соединенные Штаты, 48073
- Corewell Health William Beaumont University Hospital
-
Royal Oak, Michigan, Соединенные Штаты, 48073
- Corewell Health Children's
-
Saginaw, Michigan, Соединенные Штаты, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Соединенные Штаты, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Соединенные Штаты, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Соединенные Штаты, 48085
- Corewell Health Beaumont Troy Hospital
-
West Branch, Michigan, Соединенные Штаты, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Соединенные Штаты, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Соединенные Штаты, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Deer River, Minnesota, Соединенные Штаты, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Соединенные Штаты, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Соединенные Штаты, 55746
- Essentia Health Hibbing Clinic
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic in Rochester
-
Sandstone, Minnesota, Соединенные Штаты, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Соединенные Штаты, 55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Соединенные Штаты, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Соединенные Штаты, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Соединенные Штаты, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Соединенные Штаты, 63136
- Siteman Cancer Center at Christian Hospital
-
-
Montana
-
Anaconda, Montana, Соединенные Штаты, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Соединенные Штаты, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Соединенные Штаты, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Соединенные Штаты, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Соединенные Штаты, 59901
- Logan Health Medical Center
-
Missoula, Montana, Соединенные Штаты, 59804
- Community Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Соединенные Штаты, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Соединенные Штаты, 89183
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
New Brunswick, New Jersey, Соединенные Штаты, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Buffalo, New York, Соединенные Штаты, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Соединенные Штаты, 11501
- NYU Langone Hospital - Long Island
-
New York, New York, Соединенные Штаты, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
Ohio
-
Columbus, Ohio, Соединенные Штаты, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Соединенные Штаты, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Соединенные Штаты, 43228
- Doctors Hospital
-
Columbus, Ohio, Соединенные Штаты, 43215
- Grant Medical Center
-
Dayton, Ohio, Соединенные Штаты, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Соединенные Штаты, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Соединенные Штаты, 43015
- Grady Memorial Hospital
-
Dublin, Ohio, Соединенные Штаты, 43016
- Dublin Methodist Hospital
-
Dublin, Ohio, Соединенные Штаты, 43016
- Columbus Oncology and Hematology Associates
-
Kettering, Ohio, Соединенные Штаты, 45429
- Kettering Medical Center
-
Mansfield, Ohio, Соединенные Штаты, 44903
- OhioHealth Mansfield Hospital
-
Marion, Ohio, Соединенные Штаты, 43302
- OhioHealth Marion General Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Ontario, Oregon, Соединенные Штаты, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Соединенные Штаты, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Соединенные Штаты, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson University Hospital
-
Willow Grove, Pennsylvania, Соединенные Штаты, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Boiling Springs, South Carolina, Соединенные Штаты, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Соединенные Штаты, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Соединенные Штаты, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Соединенные Штаты, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Соединенные Штаты, 29605
- Prisma Health Cancer Institute - Butternut
-
Greer, South Carolina, Соединенные Штаты, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Соединенные Штаты, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Rapid City, South Dakota, Соединенные Штаты, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Bristol, Tennessee, Соединенные Штаты, 37620
- Bristol Regional Medical Center
-
Johnson City, Tennessee, Соединенные Штаты, 37604
- Regional Cancer Center at Johnson City Medical Center
-
Kingsport, Tennessee, Соединенные Штаты, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Соединенные Штаты, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Temple, Texas, Соединенные Штаты, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Bristol, Virginia, Соединенные Штаты, 24201
- Ballad Health Cancer Care - Bristol
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Соединенные Штаты, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Соединенные Штаты, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98122
- Swedish Medical Center-First Hill
-
-
West Virginia
-
Charleston, West Virginia, Соединенные Штаты, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Appleton, Wisconsin, Соединенные Штаты, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Соединенные Штаты, 54806
- Duluth Clinic Ashland
-
Berlin, Wisconsin, Соединенные Штаты, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Соединенные Штаты, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Cudahy, Wisconsin, Соединенные Штаты, 53110
- Aurora Saint Luke's South Shore
-
Germantown, Wisconsin, Соединенные Штаты, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Соединенные Штаты, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Соединенные Штаты, 54311
- Aurora BayCare Medical Center
-
Janesville, Wisconsin, Соединенные Штаты, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kenosha, Wisconsin, Соединенные Штаты, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Соединенные Штаты, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Соединенные Штаты, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Соединенные Штаты, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marinette, Wisconsin, Соединенные Штаты, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Соединенные Штаты, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Соединенные Штаты, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Соединенные Штаты, 53233
- Aurora Sinai Medical Center
-
Neenah, Wisconsin, Соединенные Штаты, 54956
- ThedaCare Regional Medical Center - Neenah
-
New London, Wisconsin, Соединенные Штаты, 54961
- ThedaCare Cancer Care - New London
-
Oshkosh, Wisconsin, Соединенные Штаты, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Соединенные Штаты, 54904
- ThedaCare Cancer Care - Oshkosh
-
Racine, Wisconsin, Соединенные Штаты, 53406
- Aurora Cancer Care-Racine
-
Shawano, Wisconsin, Соединенные Штаты, 54166
- ThedaCare Cancer Care - Shawano
-
Sheboygan, Wisconsin, Соединенные Штаты, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Соединенные Штаты, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Соединенные Штаты, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waupaca, Wisconsin, Соединенные Штаты, 54981
- ThedaCare Cancer Care - Waupaca
-
Wauwatosa, Wisconsin, Соединенные Штаты, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Соединенные Штаты, 53227
- Aurora West Allis Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-E5 based on the presence of an actionable mutation as defined in EAY191
-
Patient must be enrolled on the ComboMATCH Registration Protocol (EAY191) at the time of registration/randomization to the EAY191-E5 study
-
Patient must be >= 18 years of age
-
Patient must have a KRAS G12C alteration as determined by the ComboMATCH screening assessment
-
Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191-E5)
- NOTE: The current actionable marker of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website: www.ctsu.org (final URL pending)
- NOTE: Novel/Dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
-
Patient must have cytologically/histologically confirmed advanced/metastatic solid tumor
-
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
- NOTE: Patients who have progressed on a prior human epidermal growth factor receptor (EGFR) inhibitor will meet this criterion
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (or Karnofsky performance status >= 60%)
-
Patient must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) documented by imaging obtained within 28 days prior to registration/randomization
-
Patient must not have any serious active infection within 4 weeks prior to EAY191-E5 registration/randomization (e.g., requiring hospitalization and/or intravenous [IV] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible
-
Patient must have the ability to retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption
-
Patient must not have any history of or current evidence of non-infectious interstitial lung disease (ILD)/pneumonitis
-
Patient must not have a history of allergic reactions attributed to either of the study agents or to agents of similar chemical or biologic composition
-
Patient must have completed full treatment cycle 21 days prior to EAY191-E5 registration/randomization if they have received prior chemotherapy, biological cancer therapy, radiation therapy or an investigational agent/device. Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or better from any adverse events due to prior cancer therapy (with the exception of alopecia)
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration/randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for at least 6 months after the last dose of protocol treatment. Patients must not breastfeed while receiving protocol treatment and for one week (7 days) after the last dose of AMG 510 (sotorasib) and 2 months after the last dose of panitumumab
-
Patients must not have neuropathy ≥ grade 2 within 14 days prior to registration/randomization
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Human immunodeficiency virus (HIV)-infected patients no effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac history, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trail, patients should be class 2B or better
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 28 days prior to protocol registration/randomization)
-
Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase ([SGPT]) < 3 x institutional upper limit of normal (obtained ≤ 28 days prior to protocol registration/randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault (obtained ≤ 28 days prior to protocol registration/randomization)
-
COHORT I: Patient must not have colorectal cancer or non-small cell lung cancer
-
COHORT I: Patient must not have been previously treated with a KRAS G12C inhibitor
-
COHORT II: Patient must have progressed after treatment at the recommended phase II dose (RP2D) of any KRAS G12C inhibitor
- NOTE: Patients on cohort 1 who experience progression on Regimen 2 (AMG 510 [sotorasib] alone) may be eligible to enroll on cohort 2 and receive combination treatment with panitumumab and AMG 510 (sotorasib). Patients must meet performance status requirements and laboratory values as above and must be begin treatment within 7 days of enrollment. Migration to cohort 2 must take place within 6 months of progression, with no intervening anti-cancer therapy given.
- NOTE: Cohort migration following disease progression is dependent on a slot being available. MATCHBox makes the new treatment assignment following initiation of a step 2 registration for this treatment trial
-
COHORT II: Patient must not have been previously treated with a KRAS G12C inhibitor in combination with an EGFR inhibitor
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Cohort I Arm A (sotorasib, panitumumab)
Patients receive sotorasib PO QD on days 1-28 and panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Другие имена:
Undergo collection of blood
Другие имена:
Undergo CT scan
Другие имена:
Undergo tumor biopsy
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
|
|
Активный компаратор: Cohort I Arm B (sotorasib)
Patients receive sotorasib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to cohort II. Patients also undergo collection of blood samples, biopsy, and CT or MRI on study. |
Undergo MRI
Другие имена:
Undergo collection of blood
Другие имена:
Undergo CT scan
Другие имена:
Undergo tumor biopsy
Другие имена:
Given PO
Другие имена:
|
|
Экспериментальный: Cohort II (sotorasib, panitumumab)
Patients receive combination therapy as in Arm A. |
Undergo MRI
Другие имена:
Undergo collection of blood
Другие имена:
Undergo CT scan
Другие имена:
Undergo tumor biopsy
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free survival (PFS) (Cohort I)
Временное ограничение: From registration to documented disease progression or death from any cause, assessed up to 3 years
|
PFS will be compared between the arms using a one-sided log rank test with 10% type I error. Cox's proportional hazards model will be used to estimate the PFS hazard ratio between the treatment arms and a two-sided 80% confidence interval will be reported (to correspond to the one-sided 10% type I error). Confidence intervals on most other quantities will use the two-sided 90% level. |
From registration to documented disease progression or death from any cause, assessed up to 3 years
|
|
Best objective response (Cohort II)
Временное ограничение: From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
Will be evaluated using the criteria defined by Response Evaluation Criteria in Solid Tumors) version 1.1 for patients with solid tumors. |
From the start of the treatment until disease progression/recurrence, assessed up to 3 years
|
|
Overall response rate (ORR) (Cohort II)
Временное ограничение: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
The exact 90% confidence interval on the ORR (determined using the method of Atkinson and Brown) will be reported. If the number of analyzable cases is less than 35, a 5% one-sided test will still be used. |
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall survival (OS) (Cohort I)
Временное ограничение: Up to 3 years
|
OS distributions by treatment will be estimated and 90% confidence intervals on estimated rates at 6 and 12 months will be reported. The OS hazard ratio will be estimated using Cox proportional hazards model and a 90% confidence interval reported. |
Up to 3 years
|
|
ORR (Cohort I)
Временное ограничение: Up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
Up to 3 years
|
|
Disease control rates (Cohort I)
Временное ограничение: From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
Will be compared using Fisher's exact test and exact 90% confidence intervals for the rates in each arm will be computed. |
From the start of the treatment until the criteria for progression are met, assessed up to 3 years
|
|
PFS (Cohort II)
Временное ограничение: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
|
OS (Cohort II)
Временное ограничение: At 6 and 12 months, assessed up to 3 years
|
Will be estimated and 90% confidence intervals on estimated rates will be reported. |
At 6 and 12 months, assessed up to 3 years
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Kristen R Spencer, ECOG-ACRIN Cancer Research Group
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования
- Неопластические процессы
- Патологические состояния, признаки и симптомы
- Метастаз новообразования
- Аминокислоты, пептиды и белки
- Белки
- Следственные методы
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Хирургические процедуры, оперативные
- Цитологические методы
- Цитодиагностика
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Диагностические методы, хирургический
- Химические методы, аналитические
- Анализ спектра
- Панитумумаб
- Биопсия
- Обработка образца
- Магнитно -резонансная спектроскопия
- Соторазиб
Другие идентификационные номера исследования
- NCI-2022-09876
- U10CA180820 (Грант/контракт NIH США)
- NCI-2022-09876 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- EAY191-E5 (Другой идентификатор: CTEP)
- EAY191-E5 (Другой идентификатор: ECOG-ACRIN Cancer Research Group)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .